# WIKINGO Proyect Systematic Analysis

Tables & Figures.

Proyecto Vikingo September 29, 2016

proyectovikingo@proyectovikingo.es

# Contents

•	• ,	C	<b>CD</b> 1	
П.	1St.	Ωt	Tah	IPS

1	Participant characteristics	:
2	According to Local Recurrence	
3	According to Metastasis	
4	According to Exitus	
5	Incidence by outcome [95% CI]	
List	of Figures	
$\mathbf{List}$		ŗ
$\mathbf{List}$	Local Recurrence	
1	Local Recurrence	7
$\begin{array}{c} 1 \\ 2 \end{array}$	Local Recurrence	9
1 2 3	Local Recurrence	7 9 10

Table 1: Participant characteristics

L L	LL] N
N=	241
Age	66.9 (10.9) 241
Sex: Men	163 (67.6%) 241
Tumor level:	241
$0\text{-}6\mathrm{cm}$	125~(51.9%)
$7\text{-}12\mathrm{cm}$	86 (35.7%)
$13-15\mathrm{cm}$	30 (12.4%)
Tumor stage:	241
0	35~(14.5%)
I	73 (30.3%)
II	71 (29.5%)
III	62~(25.7%)
Neoadjuvant treatment	195(80.9%) 241
Type of resection:	241
Abdominoperineal resecti	on 45 (18.7%)
Anterior resection	178(73.9%)
Hartmann	18 (7.47%)
Perforation	5(2.07%) 241
Invasion circumferential margi	n 7 (2.90%) 241
Mesorrecto quality:	241
Satisfactory	184 (76.3%)
Partial	45 (18.7%)
No-satisfactory	12(4.98%)
Recidive	12(4.98%) 241
Months to recidive	13.0 [9.00;33.0] 241
Metastasis	24 (9.96%) 241
Months to Metastasis	12.0 [9.00;33.0] 241
Exitus	32 (13.3%) 241
Months to exitus	13.0 [9.00;36.0] 241

Table 2: According to Local Recurrence

			Crude		Multivariate	
	No event n= 229	Event n= 12	HR	p-value	HR	p-value
Age (10y)	6.69 (1.08)	6.75 (1.16)	1.10 [0.65;1.87]	0.719	1.15 [0.54; 2.45]	0.711
Sex: Men	156 (68.1%)	7 (58.3%)	$0.71 \ [0.22; 2.24]$	0.557	1.49 [0.41; 5.43]	0.543
Tumor level:	100 (00.170)	. (33.370)	0111 [0122,2121]	0.00.	1110 [0111, 0110]	0.010
0-6cm	119 (52.0%)	6 (50.0%)	73067807 [0.00;.]	0.998	123126393.08 [0.00; Inf]	0.998
7-12cm	80 (34.9%)	6 (50.0%)	107722802 [0.00;.]	0.998	36648205.26 [0.00; Inf]	0.998
Tumor stage:	,	,	[ /]		ι , ,	
0	35 (15.3%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.998
II	69 (30.1%)	2(16.7%)	2.23 [0.20; 24.6]	0.513	$2.24 \ [0.14;36.05]$	0.57
III	53 (23.1%)	9(75.0%)	8.82 [1.11;69.8]	0.039	5.20 [0.42;64.81]	0.2
Neoadjuvant treatment	186 (81.2%)	9 (75.0%)	0.79 [0.21; 2.93]	0.727	0.97 [0.17; 5.57]	0.97
Type of resection:	, , ,	,			-	
Abdominoperineal resection	44 (19.2%)	1 (8.33%)	0.40 [0.05; 3.13]	0.386	0.28 [0.02; 3.59]	0.327
Hartmann	18 (7.86%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999
Perforation	5 (2.18%)	0 (0.00%)	0.00 [0.00;.]	0.998	5.07 [0.00; Inf]	1
Invasion circumferential margin	4(1.75%)	3(25.0%)	21.2 [5.51;81.7]	< 0.001	2.98 [0.45;19.72]	0.257
Mesorrecto quality:						
Partial	37 (16.2%)	8 (66.7%)	15.8 [4.59;54.3]	< 0.001	12.96 [2.89;58.07]	< 0.001
No-satisfactory	12(5.24%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.998

#### Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- $\bullet~$  Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence




Table 3: According to Metastasis

			Crude		Multivaria	te	
	No event $n=217$	Event $n=24$	HR	p-value	HR	p-value	N
Age (10y)	6.70 (1.09)	6.66 (1.03)	1.00 [0.69;1.43]	0.979	0.97 [0.64; 1.45]	0.865	241
Sex: Men	145 (66.8%)	18 (75.0%)	1.51 [0.60;3.80]	0.383	1.56 [0.59; 4.12]	0.371	241
Tumor level:	( /	(	. , ,		. , ,		241
$0\text{-}6\mathrm{cm}$	114 (52.5%)	11 (45.8%)	1.01 [0.28;3.62]	0.993	1.04 [0.24; 4.40]	0.96	
7-12cm	76 (35.0%)	10 (41.7%)	1.35 [0.37; 4.92]	0.651	1.23 [0.29; 5.17]	0.777	
Tumor stage:							241
0	$32\ (14.7\%)$	3~(12.5%)	1.79 [0.40; 7.99]	0.448	1.97 [0.42; 9.23]	0.391	
II	$64\ (29.5\%)$	7~(29.2%)	$1.81 \ [0.53; 6.20]$	0.343	1.85 [0.52; 6.59]	0.34	
III	52 (24.0%)	10 (41.7%)	2.60 [0.81; 8.32]	0.107	2.02 [0.57; 7.12]	0.276	
Neoadjuvant treatment	$176 \ (81.1\%)$	19~(79.2%)	1.07 [0.40; 2.86]	0.898	1.00 [0.34; 2.94]	0.996	241
Type of resection:							241
Abdominoperineal resection	42 (19.4%)	3~(12.5%)	0.72 [0.21; 2.45]	0.602	0.93 [0.23; 3.74]	0.921	
Hartmann	$16 \ (7.37\%)$	2 (8.33%)	1.79 [0.41; 7.88]	0.439	2.70 [0.48;15.09]	0.258	
Perforation	5(2.30%)	0 (0.00%)	0.00 [0.00;.]	0.997	0.00 [0.00; Inf]	0.997	241
Invasion circumferential margin	4 (1.84%)	3~(12.5%)	7.79[2.29;26.5]	0.001	8.59 [1.71;43.27]	0.009	241
Mesorrecto quality:							241
Partial	$41\ (18.9\%)$	4~(16.7%)	$1.16 \ [0.39; 3.45]$	0.788	0.63 [0.18; 2.23]	0.474	
No-satisfactory	$10 \ (4.61\%)$	2 (8.33%)	1.29 [0.30; 5.58]	0.735	1.83 [0.36; 9.21]	0.463	

## Reference categories:

- Age, a decade
- Sex, Women
- $\bullet$  Tumor level, 13-15cm
- $\bullet~$  Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 2: Metastasis




Table 4: According to Exitus

			Crude		Multivariat	te	
	No event n= 209	Event n= 32	HR	p-value	HR	p-value	N
Age (10y)	6.67 (1.10)	6.85 (0.96)	1.18 [0.85;1.64]	0.329	1.19 [0.79; 1.78]	0.402	241
Sex: Men	139 (66.5%)	24 (75.0%)	1.49 [0.67; 3.33]	0.325	1.51 [0.63; 3.57]	0.354	241
Tumor level:	( (, -)	()	- [ , ]		. [ , ]		241
0-6cm	110 (52.6%)	15 (46.9%)	0.64 [0.25; 1.64]	0.350	0.34 [0.11; 1.11]	0.075	
7-12cm	75 (35.9%)	11 (34.4%)	0.68 [0.25; 1.85]	0.454	0.45 [0.14; 1.42]	0.171	
Tumor stage:	,	,	, ,		. , ,		241
0	32 (15.3%)	3(9.38%)	0.90 [0.24; 3.39]	0.875	1.24 [0.31; 4.99]	0.759	
II	66 (31.6%)	5 (15.6%)	0.67 [0.22; 2.04]	0.479	0.55 [0.17; 1.80]	0.324	
III	46 (22.0%)	16(50.0%)	2.07 [0.88; 4.84]	0.095	1.49 [0.56; 3.97]	0.428	
Neoadjuvant treatment	172 (82.3%)	23 (71.9%)	0.67 [0.31; 1.45]	0.313	0.74 [0.31; 1.75]	0.492	241
Type of resection:							241
Abdominoperineal resection	37 (17.7%)	8 (25.0%)	1.71 [0.75; 3.86]	0.199	3.31 [1.13; 9.73]	0.029	
Hartmann	15 (7.18%)	3(9.38%)	2.52 [0.73; 8.68]	0.142	4.26 [0.96;18.85]	0.056	
Perforation	5 (2.39%)	0 (0.00%)	0.00 [0.00;.]	0.997	0.00 [0.00; Inf]	0.997	241
Invasion circumferential margin	2(0.96%)	5 (15.6%)	8.71 [3.31;23.0]	< 0.001	14.93 [3.72;59.94]	< 0.001	241
Mesorrecto quality:							241
Partial	37 (17.7%)	8~(25.0%)	1.88 [0.83; 4.25]	0.129	0.83 [0.31; 2.23]	0.71	
No-satisfactory	10 (4.78%)	2(6.25%)	1.00 [0.23; 4.27]	0.999	1.25 [0.26; 6.05]	0.78	

## Reference categories:

- Age, a decade
- Sex, Women
- $\bullet$  Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$  Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 3: Exitus





Figure 4: Local Recurrence, according to Type of Resection:



0


0

0

18

Н

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	45	26	14	8	5	3
Ant	178	101	68	49	37	21
Н	18	7	2	0	0	0
-						

Figure 6: Survival, according to Type of Resection:




Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	1.63 [3.46; 0]	7.95 [11.81; 3.91]	7.94 [11.56; 4.17]
23	5.48 [9.5; 1.29]	9.65 [14.06; 5]	15 [20.62; 8.98]
36	9.57 [15.37; 3.37]	13.1 [18.72; 7.09]	19.58 [26.32; 12.22]
48	13 [20.11; 5.25]	16.38 [23.24; 8.91]	22.53 [30.03; 14.23]
60	13 [20.11; 5.25]	21.1 [29.88; 11.23]	24.33 [32.33; 15.39]